Innovative Cellular Therapeutics Holdings, Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
0
Ending by 2030
Jul 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 4 to 18, 2027 · next Jan 4
- 1 fee due Feb 28, 2027The maintenance fee for Inducible dominant negative PD-1 and uses in adoptive cell therapy (US 11,739,136) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 2 fees due Apr 3 to 17, 2027 · next Apr 3
- 3 fees due Jun 3 to 5, 2027 · next Jun 3
- 2 fees due Jul 2 to 9, 2027 · next Jul 2
- 1 fee due Aug 18, 2027The maintenance fee for Modified Cell Expansion and Uses Thereof (US 10,561,686) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 2 fees due Sep 19, 2027
- 3 fees due Oct 2 to 30, 2027 · next Oct 2
- 2 fees due Nov 14 to 19, 2027 · next Nov 14
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Oct 13 US 12,760,117 Nanobody Target MSLN and Uses in Chimeric Antigen Receptor Cell Therapy
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,493,139 | Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor In force (reinstated) · USPTO record | In force (reinstated) | USPTO record | |
| US 9,572,837 | Reducing immune tolerance induced by PD-L1 In force · USPTO record | In force | USPTO record | |
| US 10,865,382 | Reducing immune tolerance induced by PD-L1 In force · USPTO record | In force | USPTO record | |
| US 11,364,289 | Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor In force · USPTO record | In force | USPTO record | |
| US 12,297,267 | Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor In force · USPTO record | In force | USPTO record | |
| US 11,932,873 | Reducing immune tolerance induced by PD-L1 In force · USPTO record | In force | USPTO record | |
| US 10,619,136 | Reducing immune tolerance induced by PD-L1 In force · USPTO record | In force | USPTO record | |
| US 9,932,405 | Use of Chimeric Antigen Receptor Modified Cells to Treat Cancer In force · High confidence | In force | High confidence | |
| US 10,654,934 | Use of chimeric antigen receptor modified cells to treat cancer In force · USPTO record | In force | USPTO record | |
| US 10,793,638 | Use of Chimeric Antigen Receptor Modified Cells to Treat Cancer In force · High confidence | In force | High confidence |
Also on record, not counted in the 38: 4 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
13 pending · 4 abandoned · 11 no status recorded